Stock.adobe.com

Mercalis and PharmaCord announced the completion of their merger. The new company is rebranding itself as Valeris, which will provide services for pharma companies throughout the commercialization process. This includes data and strategic insights, patient support services, and healthcare provider engagement tools.

What is the state of M&A in the pharma industry?

According to Valeris, it aims to improve the patient experience by streamlining access, reducing barriers, and supporting adherence.

In a press release, Valeris’ chief executive officer Rob Truckenmiller (former CEO of PharmaCord) said, “To remain effective and relevant, patient support must evolve, shifting from commoditized models to dynamic, data-driven ecosystems designed for long-term value. With deep expertise in patient support services and market access, an advanced technology infrastructure, and an experienced commercial team, Valeris is fully committed to power life sciences companies and enhance patient lives."

Valeris’ president Scott Dulitz (former Mercalis CEO) also said in the same press release, “Valeris is the product of over 33 years of industry expertise. This brand marks more than a name change––it signals our commitment to leading progress in healthcare. By bringing together proven capabilities under one purpose-driven organization, we're making the path from diagnosis to patient outcomes more seamless, more supported, and more human. We're built to help our partners thrive in today's complexity––and shape what comes next."

The merger was first announced in March of this year and is backed by investment firms Permira and Odyssey Investment Partners.

In March, Truckenmiller said of the recently announced merger, “This combination is about more than growth––it’s about impact and transformation to meet evolving manufacturer and patient needs. By uniting PharmaCord’s deep expertise in hub services with Mercalis’s established leadership in end-to-end patient access solutions and robust infrastructure, we are building a next-generation platform that redefines how life science companies bring innovative therapies to market. Together we will unlock new efficiencies, accelerate patient access, create a seamless experience for healthcare providers and patients alike, and provide a highly compelling opportunity for employees.”

In the same press release, Dulitz added, “This merger marks an exciting milestone for Mercalis and our team as we continue our journey of transformative growth and innovation alongside PharmaCord. Mercalis and PharmaCord share a noble mission––to enhance the lives of the patients we serve. By joining forces, we are strengthening our ability to provide seamless, fully integrated commercialization support for our life science customers and their patients. I want to express my gratitude to Odyssey for their strategic partnership over the past seven years and look forward to collaborating with Rob and the Permira team to further our shared vision. I am truly excited about the opportunities this merger brings to our combined ecosystem and the positive impact it will have on the healthcare industry.”

At the time, PharmaCord announced that the new company would be majority owned by funds advised by Permira. The financial terms of the transaction have not been disclosed.

In the initial announcement, Permira partner Jon Maschmeyer said, “The combination of PharmaCord and Mercalis will form one of the largest independent patient access companies in the market, delivering the full breadth of solutions with greater reach and efficiency. With our support, the combined company will have the resources to continue innovating and catering to the evolving needs of patients and biopharmaceutical companies. We look forward to the opportunity to raise the bar for patient access and drive the industry forward.”

Maschmeyer was also a member of PharmaCord’s board of directors at the time.

Sources

1. Valeris Launches with a Fully Integrated Vision for Life Sciences Companies. Mercalis. May 27, 2025. https://www.prnewswire.com/news-releases/valeris-launches-with-a-fully-integrated-vision-for-life-sciences-companies-302464683.html
2. PharmaCord and Mercalis to Merge, Creating Next-Generation Platform to Meet Evolving Needs of the Biopharmaceutical Industry. PharmaCord. March 12, 2025. Accessed May 27, 2025. https://www.businesswire.com/news/home/20250312808363/en/PharmaCord-and-Mercalis-to-Merge-Creating-Next-Generation-Platform-to-Meet-Evolving-Needs-of-the-Biopharmaceutical-Industry